After completing its reverse takeover of Titan Medical on October 11th, Conavi Medical has completed its plan to voluntarily delist from the TSX and subsequently list on the TSX Venture Exchange (TSXV). Trading of Conavi’s common shares on the TSXV commenced today under the new trading ticker “CNVI”.
Tom Looby, Conavi’s CEO, said in a statement the completion of the reverse takeover and listing on the TSXV comes at a pivotal moment in the company’s evolution. “As we continue to advance the Novasight Hybrid System, which is the first technology to combine two major intravascular imaging modalities – IVUS and OCT – to help guide common minimally invasive coronary procedures, we believe gaining access to the public capital markets will enhance our financial strength and fuel our growth strategy.”
The Novasight Hybrid System has 510(k) clearance from the U.S. FDA; and regulatory approval for clinical use from Health Canada, China’s National Medical Products Administration, and Japan’s Ministry of Health, Labor and Welfare.
